Avalon Trust’s Biogen BIIB Stock Holding History

Avalon Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$1.26K	–	456
2025 Q3	$1.26K	Buy	+9	New	+$1.22K	﹤0.01%	489
2025 Q1	–	Sell	-42	Closed	-$6.42K	–	435
2024 Q4	$6.42K	Buy	+42	New	+$7.08K	﹤0.01%	344

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avalon Trust's BIIB Position: Q4 2025 in Review

Avalon Trust sold out of Biogen (BIIB) in Q4 2025, closing a stake of 9 shares — an estimated $1.26K sold.

Avalon Trust first reported a position in BIIB in Q4 2024 and held it in 2 quarters. The position peaked at $6.42K in Q4 2024. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Avalon Trust reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Avalon Trust sold 9 Biogen shares in Q4 2025, an estimated $1.26K.
Avalon Trust first reported a position in Biogen in Q4 2024 and held it in 2 quarters.
Avalon Trust's Biogen position peaked at $6.42K in Q4 2024.
1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Avalon Trust's 13F filing for Q4 2025, filed 9 Feb 2026.